



Bringing a new approach to medical cannabis
Building bridges between patients and science

Cannabis Science Inc.
548 Market Street
Suite 16645
San Francisco, CA 94104

OTCBB
CBIS

Investor Information

Ticker Symbol
OTCBB: CBIS

SEC Reporting Status
Fully Reporting Company

Recent Share Price
\$.27

52 Week High / Low
2.10 / .05

Authorized Shares
30,000,000

Outstanding Shares
14,679,000

Transfer Agent
Routh Stock Transfer
Plano, TX 75024

Chief Executive Officer
Steve Kubby



Cannabis Science works with World Authorities on phytocannabinoid science targeting critical illnesses. Adhering to scientific methodologies to develop, produce, and commercialize phytocannabinoid based pharmaceutical products

Why Invest in Cannabis Science Inc.?

Recent advances in science have opened the door to develop, produce, and commercialize, a variety of effective whole plant cannabinoid based pharmaceutical products with a wide variety of important applications.

Although cannabis has been used medicinally for thousands of years, until very recently little was known about how it actually worked. Some uses of cannabis are well known, such as alleviating nausea and stimulating the appetite for people with AIDS and cancer.

Other well-known uses include chronic pain, and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its effectiveness in alleviating certain autoimmune disorders such a Crohn's Disease.

Cannabis Sciences team of scientists will develop more effective ways to produce and commercialize the production of whole plant cannabinoid based pharmaceutical products. Even today new uses for cannabis are being found, such as the recent discovery that topical cannabis preparations can be effective against MRSA, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis, and burns, but also neuropathic pain, for which there are few effective treatments.

In 2001, an article published in the Canadian Medical Association Journal revealed that, based on self-identified needs, an estimated 2% (or 400,000) Canadian adults were already using cannabis for medical purposes. That number would extrapolate into roughly 4 million in the US. Consequently, we believe that it would not be unreasonable to think that the global medical cannabis market will potentially reach several billion dollars.

Recent Cannabis Science Inc. Headlines

6/18/2009 CSI Development Team Recommends Patent Filings for Its Cannabis Processing and Drug Delivery Systems

6/12/2009 CSI Appoints Former Upjohn Senior Research Scientist Mary J. Ruwart, Ph.D. to Vice President of Research & Development (VP R&D) Further Expanding Its Team of Drug Development Specialists

Disclaimer: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this summary, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.